Novo Nordisk expresses optimism on diabetes drug

11/16/2007 | Reuters

Novo Nordisk expressed confidence that its Type 2 diabetes drug liraglutide is as effective as Eli Lilly & Co.'s Byetta drug in treating the disease. The company is planning to bolster its U.S. sales force to promote its drug to general practitioners -- a move that could give the firm a competitive advantage over a long-acting version of Byetta, a Novo Nordisk official said at a health summit.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL